Overview

Efficacy Study of Andrographis Paniculata Purified Standardized Extract (ApE) in Patients With Multiple Sclerosis (MS)

Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of ApE coated tablets, on the relapse rate in a group of relapsing remitting multiple sclerosis (RRMS) patients, as compared to a placebo group in a period of 12 months. This study will also determine the safety and tolerability of the drug administered over interferon beta vs. administration of a placebo formulation (also over interferon) during the evaluation period. Response will be assessed and measured by daily self patient recording, monthly clinical neurologist, and every three months serological and magnetic resonance parameters. Place of Study: National study in Chile with one center at the Regional Hospital in the city of Valdivia, including 30 patients enrolled by their respective neurologists.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Universidad Austral de Chile
Collaborators:
Comisión Nacional de Investigación Científica y Tecnológica
University of Chile
Treatments:
Andrographolide